Category: Research

The UAB O’Neal Cancer Center is playing a prominent role at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

Faculty, physicians, scientists, and trainees from the UAB O’Neal Cancer Center joined oncology leaders from around the world at the 2026 (ASCO) Annual Meeting.

Faculty and researchers from the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham (UAB) will join oncology professionals from around the world at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2 in Chicago.

UAB's partnership with Infirmary Health offers patients around the southeast aceess to UAB-trained physicians, clinical trials, and all of the resources of the UAB O'Neal Cancer Center.

Andrea Comba, Ph.D., recently secured the V Foundation’s V Scholar Award through the support of her colleagues at the O’Neal Cancer Center.

The UAB O’Neal Cancer Center is pleased to announce the latest recipients of the O’Neal NextGen Scholar Awards. This year, two of these awards were generously funded by the Breast Cancer Research Foundation of Alabama (BCRFA).

The UAB O’Neal Cancer Center is pleased to announce the latest recipients of the O’Neal NextGen Scholar Awards. These awards are funded by the Young Supporters Board (YSB) of the O’Neal Cancer Center.

The UAB O’Neal Cancer Center is pleased to announce the latest O’Neal Invests grant awards. In this cycle, three grants received the award, including two funded by the BCRFA and by the Children’s of Alabama Hope Fund, respectively.

A multidisciplinary team at UAB successfully performed Alabama’s first deceased-donor bone marrow transplant.

Jorge Cortes, M.D. will join the Division of Hematology and Oncology as Chief of Hematology; furthermore, Cortes will serve as the Deputy Director of the O'Neal Cancer Center. Similarly, Mehmet Akce, M.D., will serve as Interim Chief of Oncology.

The University of Alabama System Board of Trustees has appointed Anindya Dutta, MBBS, Ph.D., as the next holder of the O’Neal-Sokol Breast Cancer Research Foundation of Alabama (BCRFA) Endowed Chair.

Nature Cancer magazine published a study led by Dr. Stringer-Reasor that highlights a promising advance in the treatment of one of the most challenging complications of breast cancer, leptomeningeal metastasis.

The UAB O’Neal Cancer Center is pleased to announce the latest O’Neal Invests grant awards as part of the 2025 fall cycle.

The UAB O’Neal Cancer Center is pleased to announce that the Breast Cancer Research Foundation of Alabama (BCRFA) has generously funded two grants through the 2025 fall cycle of O’Neal Invests.

The UAB O’Neal Comprehensive Cancer Center hosted its 2024 Iron Strong Awards July 12, honoring nine cancer clinical trial survivors.

The UAB O’Neal Comprehensive Cancer Center is pleased to announce that the Breast Cancer Research Foundation of Alabama (BCRFA) has generously funded […]

The UAB O’Neal Comprehensive Cancer Center is pleased to announce the latest O’Neal […]

The UAB O’Neal Comprehensive Cancer Center is pleased to announce its latest O’Neal Invests grant awards for its fall 2024 cycle.

UAB Medicine and the UAB O’Neal Comprehensive Cancer Center invite all medical professionals involved in caring for patients with lung cancer to attend this annual CME-accredited event on November 1-2, 2024.

The UAB O’Neal Comprehensive Cancer Center hosted its 2024 Iron Strong Awards July 12, honoring nine cancer clinical trial survivors.

The UAB O’Neal Comprehensive Cancer Center is pleased to announce that the BCRFA has generously funded two catalyst grants through the spring cycle of O’Neal Invests.

The UAB O’Neal Comprehensive Cancer Center is pleased to announce its spring 2024 O’Neal Invests grant awards.

New technology presents new opportunities in patient care, something that Yogesh Kumar, Ph.D., knew well when he began researching the use of machine-learning software in cancer treatment. When he received this year’s Mary Ann Harvard NextGen Scholar Award for his work integrating artificial intelligence into radiotherapy, he knew he was on the right track.

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy.